{"id":"W2098491904","doi":"10.1016/s0140-6736(06)68439-0","title":"Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","year":2006,"lang":"en","type":"article","venue":"The Lancet","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1637,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; McGill University","funders":"GlaxoSmithKline","keywords":"Bivalent (engine); Medicine; Human papillomavirus; Human papillomavirus vaccine; Randomized controlled trial; Virus-like particle; Vaccine efficacy; Virology; Vaccination; Internal medicine; Biology; Cervical cancer; Gardasil; Cancer; Recombinant DNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}